Cell and gene therapy sector faces infrastructure and affordability challenges

The cell and gene therapy (CGT) sector is transitioning from proving scientific possibility to addressing the logistical and economic challenges of large-scale delivery. As these therapies move from treating rare diseases to more common conditions like high cholesterol, stakeholders are facing critical questions regarding affordability, value, and infrastructure.

Industry leaders emphasize that scientific breakthroughs alone do not guarantee patient access. Delivering CGT requires a highly integrated ecosystem involving manufacturers, hospitals, regulators, and payers. Alexander Seyf, CEO of Act for Hope, argues that collaboration must become a foundational infrastructure—incorporating shared standards and interoperable digital systems—to prevent fragmentation in the supply chain.

Simultaneously, the expansion of the CGT market presents financial risks for employers and healthcare systems. Sarah Emond, CEO of the Institute for Clinical and Economic Review (ICER), notes that as the eligible patient population grows, the industry must balance innovation with long-term durability of treatment outcomes and sustainable payment models.